Latham Advises on £133.4 Million Placing by Dechra Pharmaceuticals

London equity capital markets team represents Investec in placing by veterinary products developer.

June 09, 2020

Latham & Watkins advised Investec as the sole bookrunner on a £133.4 million cash placing by Dechra Pharmaceuticals PLC (Dechra), an international veterinary pharmaceuticals and related products business. The placing represents approximately 5% of Dechra’s previously issued share capital.

The transaction builds on Latham’s significant equity capital markets activity in London over the past two months as many London listed companies seek to raise equity.

Latham’s team was led by London corporate partner Chris Horton, with associates Sean Meehan and Frederick Gardner. Partner Ryan Benedict and associate Sarah Youssefi advised on US securities law matters. 

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.